← Back to Clinical Trials
Recruiting NCT04887623

NCT04887623 Dynamics of Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04887623
Status Recruiting
Phase
Sponsor University Hospital Hradec Kralove
Condition COVID-19 Respiratory Infection
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2021-04-01
Primary Completion 2025-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2021-04-01 with a primary completion date of 2025-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients requiring admission to the hospital due to a moderate and severe COVID-19 infection may differ in their ability to respond to viral infection and to eliminate viral load. Several comorbidities and interventions like antivirotic or antiinflammatory treatment may also modify expected patients response and decrease of viral load. In this observational study, evolution of selected inflammatory markers, indicators of severity of infection and patient characteristics will be followed and recorded in hospitalized patients with COVID-19.

Eligibility Criteria

Inclusion Criteria: * SARS CoV2 positive test within last 14 day * bilateral infiltrates on chest X.ray or CT * need for oxygen to keep pulse oximetry saturation above 92% or other respiratory support measures (HFNO, non-invasive ventilation or invasive ventilation) Exclusion Criteria: * known history of intersticial lung disease * known history of congestive heart failure

Contact & Investigator

Central Contact

Pavel Dostál, MD, PhD

✉ pavel.dostal@fnhk.cz

📞 +420602455632

Principal Investigator

Vladimir Palicka, MD, CSc.

STUDY CHAIR

University Hospital Hradec Kralove

Frequently Asked Questions

Who can join the NCT04887623 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying COVID-19 Respiratory Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04887623 currently recruiting?

Yes, NCT04887623 is actively recruiting participants. Contact the research team at pavel.dostal@fnhk.cz for enrollment information.

Where is the NCT04887623 trial being conducted?

This trial is being conducted at Hradec Králové, Czechia.

Who is sponsoring the NCT04887623 clinical trial?

NCT04887623 is sponsored by University Hospital Hradec Kralove. The principal investigator is Vladimir Palicka, MD, CSc. at University Hospital Hradec Kralove. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology